MDM2 suppresses p73 function without promoting p73 degradation

Molecular and Cellular Biology

Volumn 19, Issue 5, 1999, Pages 3257-3266

  Zeng, Xiaoya ^a   Chen, Lihong ^b   Jost, Christine A ^c   Maya, Ruth ^d   Keller, David ^a   Wang, Xinjiang ^d   Kaelin Jr , William G ^c,e   Oren, Moshe ^d   Chen, Jiandong ^b   Lu, Hua ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ANIMALIA;

EID: 0032961828     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.5.3257     Document Type: Article

References (66)

1. Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184.
2. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
3. Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren. 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8:1739-1749.
4. Bian, J., and Y. Sun. 1997. P53CP, a putative p53 competing protein, that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc. Natl. Acad. Sci. USA. 94:14753-14758.
5. Bottger, A., V. Bottger, A. Sparks, W. L. Liu, S. F. Howard, and D. P. Lane. 1997. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860-869.
6. Cahilly-Snyder, L., T. Yang-Feng, U. Francke, and D. L. George. 1987. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet. 13:235-244.
7. Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
8. Chen, J., J. Lin, and A. J. Levine. 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:142-152.
9. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16:2445-2452.
10. Chen, L., S. Agrawal, W. Zhou, R. Zhang, and J. Chen. 1998. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95:195-200.
11. Cordon Cardo, C., E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, V. Marechal, J. Chen, M. F. Brennan, and A. J. Levine. 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:794-799.
12. Dulic, V., W. K. Kaufmann, S. J. Lees, T. D. Tisty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023.
13. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinder, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
14. Elenbaas, B., M. Dobbelstein, J. Roth, T. Shenk, and A. J. Levine. 1996. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2:439-451.
15. Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565-1569.
16. Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301-306.
17. Freedman, D. A., C. B. Epstein, J. C. Roth, and A. J. Levine. 1997. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 3:248-259.
18. Gottlieb, T. M., and M. Oren. 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta Gene Struct. Expression 1287:77-102.
19. Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. P300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405-415.
20. Gu, W., X. L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819-823.
21. Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596-1606.
22. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
23. Hermeking, H., C. Lengauer, K. Polyak, T. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and B. Vogelstein. 1997. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1:3-11.
24. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
25. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
26. Jost, C. A., D. Ginsberg, and W. J. Kaelin. 1996. A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. Virology 220:78-90.
27. Jost, C. A., M. C. Marin, and W. G. Kaelin. 1997. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191-194.
28. 27a. Jost, C. A., and W. G. Kaelin. Unpublished data.
29. Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. Biscan, A. Valent, A. Minty, P. Chalon, J. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
30. Ko, J. L., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10: 1054-1072.
31. Kovalev, S., N. Marchenko, S. Swendeman, M. LaQuaglia, and U. M. Moll. 1998. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 9:897-903.
32. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by mdm2. Nature 387:299-303.
33. Kubbutat, M. H., R. L. Ludwig, M. Ashcroft, and K. H. Vousden. 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18:5690-5698.
34. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
35. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827.
36. Lin, J., J. Chen, B. Elenbass, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to MDM2 and the adenovirus 5 E1B 55-kd protein. Genes Dev. 8:1235-1246.
37. Lozano, G., and O. L. de Montes. 1998. MDM2 function. Biochim. Biophys. Acta Rev. Cancer 1377:M53-M57.
38. Lu, H., and A. J. Levine. 1995. Human TAF-31 is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92:5154-5158.
39. Lu, H., J. Lin, J. Chen, and A. J. Levine. 1996. Regulation of p53 transcriptional function: TAFs and MDM2. Harvey Lect. 90:81-93.
40. Lu, H., V. Taya, M. Ikeda, and A. J. Levine. 1998. Phosphorylation of p53 at serine 389 is responsive uniquely to UV- but not to gamma- and etoposide-induced DNA damage. Proc. Natl. Acad. Sci. USA 95:6399-6402.
41. Marin, M. C., C. A. Jost, M. S. Irwin, J. A. DeCaprio, D. Caput, and W. G. Kaelin. 1998. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 18:6316-6324.
42. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
43. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The radm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
44. Momand, J., and G. P. Zambetti. 1997. Mdm-2: "big brother" of p53. J. Cell. Biochem. 64:343-352.
45. Oca Luna, R. M., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
46. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
47. Oliner, J. D., J. A. Pletenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
48. Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimira, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839-843.
49. Plette, J., H. Neel, and V. Marechal. 1997. Mdm2: keeping p53 under control. Oncogene 15:1001-1010.
50. Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein. 1997. A model for p53-induced apoptosis. Nature 389:300-305.
51. Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
52. Prabhu, N. S., K. Somasundaram, K. Satyamoorthy, M. Herlyn, and W. S. El-Deiry. 1998. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol. 13:5-9.
53. Schmale, H., and C. Bamberger. 1997. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363-1367.
54. Shikama, N., L. Lyon, and N. B. La Thangue. 1997. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 7:230-236.
55. Tharakan, J. 1994. Immunoaffinity purification, p. 327-340. In V. S. Malik and E. P. Lillehoj (ed.), Antibody techniques. Academic Press, Inc., New York, N.Y.
56. Thut, C. J., J. L. Chen, R. Klemin, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267:100-104.
57. Thut, C. J., J. A. Goodrich, and R. Tjian. 1997. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11:1974-1986.
58. Trink, B., K. Okami, L. Wu, V. Sriuranpong, J. Jen, and D. Sidransky. 1998. A new human p53 homologue. Nat. Med. 4:747-748.
59. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
60. Xiao, Z., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and D. Livingston. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
61. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. P21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
62. Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305-316.
63. Zeng, X. Y., A. J. Levine, and H. Lu. 1998. Non-p53 p53RE binding protein, a human transcription factor functionally analogous to p53. Proc. Natl. Acad. Sci. USA 95:6681-6686.
64. Zeng, X. Y., A. Miller, W. Yuan, R. Kwok, R. Goodman, and H. Lu. p73 and p53 activate transcription through interaction with different domains of p300/CBP. Submitted for publication.
65. 63a. Zeng, X. Y., and H. Lu. Unpublished data.
66. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.